RWD137 Real-World Treatment Patterns of First-Line (1L) Ibrutinib in Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL): Insights into Therapy Interruptions, Discontinuation and Next Treatment
Abstract
Authors
John Burke Zackon Ira Brittani Wayne Yunfei Wang John Murphy Jennifer Prescott Shravanthi R. Gandra Siyang Leng Enrico De Nigris